The analyzed cancer samples showed CSPG4 expression that was either strong (PTC = 11/25, FTC = 7/22, ATC = 1/12), intermediate (PTC = 11/25, FTC = 15/22, ATC = 11/12), or weak (PTC = 3), with patterns of expression including cytoplasmic (43 of 59 cancer samples) and combined membranous and cytoplasmic (16 of 59 cancer samples); contrarily, the nine non-cancer thyroid samples demonstrated low or negative CSPG4 expression (Fig. 1B, C, Supplementary Fig. 1A, B). This evidence concerns the gene CSPG4 and thyroid cancer, nonmedullary, 2.